JP2021528423A5 - - Google Patents
Info
- Publication number
- JP2021528423A5 JP2021528423A5 JP2020570938A JP2020570938A JP2021528423A5 JP 2021528423 A5 JP2021528423 A5 JP 2021528423A5 JP 2020570938 A JP2020570938 A JP 2020570938A JP 2020570938 A JP2020570938 A JP 2020570938A JP 2021528423 A5 JP2021528423 A5 JP 2021528423A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- bispecific antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688251P | 2018-06-21 | 2018-06-21 | |
| US62/688,251 | 2018-06-21 | ||
| PCT/US2019/038163 WO2019246356A1 (en) | 2018-06-21 | 2019-06-20 | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528423A JP2021528423A (ja) | 2021-10-21 |
| JP2021528423A5 true JP2021528423A5 (cg-RX-API-DMAC7.html) | 2022-06-23 |
| JP7403480B2 JP7403480B2 (ja) | 2023-12-22 |
Family
ID=67254001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570938A Active JP7403480B2 (ja) | 2018-06-21 | 2019-06-20 | 二重特異性抗cd3×muc16抗体および抗pd-1抗体で癌を治療する方法 |
Country Status (26)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| ES3009025T3 (en) | 2018-08-31 | 2025-03-25 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies |
| JP2023539525A (ja) * | 2020-09-02 | 2023-09-14 | ジェンマブ エー/エス | 抗体療法 |
| NL2027601B1 (en) * | 2021-02-19 | 2022-09-19 | Crm Therapeutics B V | Target mediated endocytotic drug delivery |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| CN117015394A (zh) * | 2021-03-12 | 2023-11-07 | 博际生物医药科技(杭州)有限公司 | 结合人TGFβ和PD-L1的双功能分子及其应用 |
| EP4308160A4 (en) * | 2021-03-18 | 2025-07-02 | Memorial Sloan Kettering Cancer Center | METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS |
| CN117320700A (zh) * | 2021-04-02 | 2023-12-29 | 瑞泽恩制药公司 | 含有抗muc16 x抗cd3双特异性抗体的稳定制剂 |
| JPWO2023033022A1 (cg-RX-API-DMAC7.html) | 2021-08-31 | 2023-03-09 | ||
| MX2024006187A (es) * | 2021-11-24 | 2024-08-14 | Regeneron Pharma | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. |
| MX2024008055A (es) * | 2022-01-07 | 2024-09-06 | Regeneron Pharma | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. |
| US20250092135A1 (en) * | 2022-01-10 | 2025-03-20 | Nanjing Leads Biolabs Co., Ltd. | Antibody and use thereof |
| WO2023176881A1 (ja) * | 2022-03-16 | 2023-09-21 | 第一三共株式会社 | 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| ES2954153T3 (es) | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| MX2019004327A (es) * | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| WO2018099539A1 (en) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
-
2019
- 2019-06-19 TW TW113114645A patent/TW202504917A/zh unknown
- 2019-06-19 TW TW108121196A patent/TWI890661B/zh active
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en not_active Ceased
- 2019-06-20 PL PL19739472.9T patent/PL3810281T3/pl unknown
- 2019-06-20 EP EP24176671.6A patent/EP4424712A3/en active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
- 2019-06-20 KR KR1020217000649A patent/KR102870971B1/ko active Active
- 2019-06-20 CN CN201980040564.9A patent/CN112312970B/zh active Active
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 AU AU2019290170A patent/AU2019290170B2/en active Active
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
- 2019-06-20 MA MA52962A patent/MA52962B1/fr unknown
- 2019-06-20 MY MYPI2020006505A patent/MY202134A/en unknown
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 ES ES19739472T patent/ES2984972T3/es active Active
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 HU HUE19739472A patent/HUE067985T2/hu unknown
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 MA MA71708A patent/MA71708A/fr unknown
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 IL IL279251A patent/IL279251B2/en unknown
-
2020
- 2020-12-07 ZA ZA2020/07599A patent/ZA202007599B/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
- 2020-12-16 MX MX2025008444A patent/MX2025008444A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050618A5 (cg-RX-API-DMAC7.html) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2019515008A5 (cg-RX-API-DMAC7.html) | ||
| JP2022078265A5 (cg-RX-API-DMAC7.html) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2020508317A5 (cg-RX-API-DMAC7.html) | ||
| JP2019519499A5 (cg-RX-API-DMAC7.html) | ||
| JP2022532490A5 (cg-RX-API-DMAC7.html) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2023505218A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500822A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512851A5 (cg-RX-API-DMAC7.html) | ||
| TW202320827A (zh) | 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合 | |
| JP2023519807A5 (cg-RX-API-DMAC7.html) | ||
| JP2025134086A (ja) | 関節リウマチを有する対象における疼痛を治療するための組成物および方法 | |
| JP2025509567A5 (cg-RX-API-DMAC7.html) | ||
| JP2025502061A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518348A5 (cg-RX-API-DMAC7.html) | ||
| TW202034925A (zh) | Cdk4/6抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| CN117693350A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| JP2024542879A5 (cg-RX-API-DMAC7.html) | ||
| IL314851A (en) | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer | |
| NZ781933B2 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |